文献速递病毒性肝炎新发突发、热带与寄生虫病

挪威消除丙型肝炎作为公共卫生威胁的进展监测:针对注射吸毒者与移民的建模研究

Monitoring Progress Towards the Elimination of Hepatitis C as a Public Health Threat in Norway: A Modelling Study Among People Who Inject Drugs and Immigrants.
PubMed 文献 · J Infect Dis · 2024-01-01

该建模研究采用随机区室模型,结合国家数据源、文献与专家意见,估计挪威活动性注射吸毒者(PWID)中丙型肝炎新发感染数及活动性PWID、既往PWID和移民中慢性感染患病率至2022年。模型估计2022年活动性PWID新发感染30例(95%CrI 13-52),即0.37/100(95%CrI 0.17-0.65),较2000年峰值726例(95%CrI 506-1067)下降;2022年所有组别慢性感染者估计为3202例(95%CrI 1273-6601)。敏感性分析结果稳健。结论认为挪威在疫情集中、减害服务覆盖率高且无治疗限制的环境中展示了消除丙型肝炎的可行性,仍需持续努力以进一步降低传播和负担。

要点

  • 2022年活动性PWID新发感染估计为30例(95%CrI 13-52),即0.37/100(95%CrI 0.17-0.65)。
  • 2000年活动性PWID新发感染峰值估计为726例(95%CrI 506-1067)。
  • 2022年所有组别慢性感染者估计为3202例(95%CrI 1273-6601)。

核心结论

  • 挪威在疫情集中、减害服务覆盖率高且无治疗限制的环境中展示了消除丙型肝炎的可行性。
  • 仍需持续努力以进一步降低挪威丙型肝炎的传播和负担。

研究设计与样本

  • 研究构建随机区室模型,使用国家数据源、文献和专家意见进行参数化。
  • 模型估计挪威活动性PWID中丙型肝炎发病率,以及活动性PWID、既往PWID和移民中慢性感染患病率至2022年。
  • 结果报告为中位数及95%可信区间(CrI)。

主要发现

  • 模型估计2022年活动性PWID新发感染30例(95%CrI 13-52),即0.37/100(95%CrI 0.17-0.65)。
  • 活动性PWID新发感染从2000年峰值726例(95%CrI 506-1067)下降。
  • 2022年所有组别慢性感染者估计为3202例(95%CrI 1273-6601)。
  • 敏感性分析结果稳健。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The global incidence target for the elimination of hepatitis C among people who inject drugs (PWID) is <2/100. In Norway, the hepatitis C epidemic is concentrated in PWID. Immigrants are the second most important risk group for chronic infection. We modelled the incidence of hepatitis C among active PWID, and the prevalence of chronic infection among active PWID, ex-PWID, and immigrants in Norway to 2022. METHODS: We built a stochastic compartmental model, which was informed using data from national data sources, literature, and expert opinion. We report median values with 95% credible intervals (CrI). RESULTS: The model estimated 30 (95% Crl, 13-52) new infections among active PWID in 2022, or 0.37/100 (95% Crl, 0.17-0.65), down from a peak of 726 (95% Crl, 506-1067) in 2000. Across all groups, the model estimated 3202 (95% Crl, 1273-6601) chronically infected persons in 2022. Results were robust in sensitivity analyses. CONCLUSIONS: Norway provides an example of the feasibility of hepatitis C elimination in a setting with a concentrated epidemic, high coverage of harm reduction services, and no treatment restrictions. Continued momentum is needed to further reduce the transmission and burden of hepatitis C in Norway.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Whittaker R, Midtbø JE, Kløvstad H, et al. Monitoring Progress Towards the Elimination of Hepatitis C as a Public Health Threat in Norway: A Modelling Study Among People Who Inject Drugs and Immigrants. J Infect Dis. 2024. PMID: 38537267. doi:10.1093/infdis/jiae147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。